Selective laser trabeculoplasty (SLT) plays a critically important role in the treatment of glaucoma. Published in The Lancet, the pivotal results of the LiGHT trial conclude that SLT should be used as the preferred first-line treatment for patients with glaucoma or ocular hypertension.1
Around the world, thousands of physicians are deploying the SLT procedure as a primary therapy tool that stimulates the eye’s natural healing response to effectively manage their patients’ intraocular pressure without the burn and scar tissue associated with argon laser trabeculoplasty. With Tango Reflex from Ellex, you can use SLT to determine the location of the pathology and treat glaucoma effectively and safely, delivering better patient outcomes.
Contact: Ellex (AUS) 08 7074 8200
- LiGHT study, The Lancet. 393.10175